CLASS ACTION UPDATE for LK, INO and GOSS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / April 8, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

Luckin Coffee Inc. (NASDAQ:LK)
LK Lawsuit on behalf of: investors who purchased May 17, 2019 – April 2, 2020
Lead Plaintiff Deadline: April 13, 2020
Join the action: https://www.zlk.com/pslra-1/luckin-coffee-inc-loss-form?wire=3&prid=5954

Allegations: Luckin Coffee Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) certain of Luckin's financial performance metrics, including per-store per-day sales, net selling price per item, advertising expenses, and revenue contribution from "other products" were inflated; (ii) Luckin's financial results thus overstated the Company's financial health and were consequently unreliable; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

To learn more about the Luckin Coffee Inc. class action, contact jlevi@levikorsinsky.com.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO)
INO Lawsuit on behalf of: investors who purchased February 14, 2020 – March 9, 2020
Lead Plaintiff Deadline: May 12, 2020
Join the action: https://www.zlk.com/pslra-1/inovio-pharmaceuticals-inc-loss-form?wire=3&prid=5954

According to a filed complaint, throughout the class period, defendants made misleading statements about the company's development of a purported vaccine for the novel coronavirus, artificially inflating the company's share price and resulting in significant investor losses.

To learn more about the Inovio Pharmaceuticals, Inc. class action, contact jlevi@levikorsinsky.com.

Gossamer Bio, Inc. (NASDAQ:GOSS)
GOSS Lawsuit on behalf of: investors who purchased common stock between February 8, 2019 and December 13, 2019 and/or who acquired Gossamer shares pursuant or traceable to Gossamer's documents issued in connection with its February 8, 2019 initial public offering.
Lead Plaintiff Deadline: June 2, 2020
Join the action: https://www.zlk.com/pslra-1/gossamer-bio-inc-loss-form?wire=3&prid=5954

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose: (1) the reasons for Gossamer's GB001 trial failures; (2) the purported clinical validation of Novartis' oral DP2 antagonist; and (3) that, as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

To learn more about the Gossamer Bio, Inc. class action, contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 584400